Core Insights - The article discusses the successful hosting of the "Qihang·2025 Financial Annual Conference" in Beijing, where Tang Yefeng, Vice President and Secretary of the Board of Jiangsu Hanbang Technology Co., Ltd. (Hanbang Technology), shared insights on the company's post-IPO development, core technology industrialization, domestic substitution progress in chromatography equipment, and the "14th Five-Year Plan" strategic layout [1][2]. Company Overview - Hanbang Technology, established in 1998, focuses on chromatography technology, integrating R&D, production, and sales, primarily serving the pharmaceutical and life sciences sectors with professional separation and purification equipment, consumables, and related solutions [3]. - The company has a leading position in the domestic chromatography separation and purification equipment market, holding a 39.2% market share in production-level small molecule separation and purification equipment, ranking first, and an 8.8% market share in large molecule equipment, ranking third [3]. IPO Impact - The IPO completed in May 2025 is viewed as a significant milestone, acting as an "accelerator" for high-quality development across three dimensions: enhancing capital strength, improving governance structure, and increasing resource integration capabilities [4]. - Funds raised from the IPO are directed towards projects such as the annual production of 1,000 liquid chromatography equipment and the establishment of a chromatography separation equipment R&D center, which will support capacity expansion and sales growth [4]. Value Communication - The role of the Secretary of the Board is crucial in conveying value for technology-intensive newly listed companies, focusing on translating complex technical systems into understandable market value propositions and establishing communication channels with investors [5]. Technological Advancements - Hanbang Technology has developed a unique technology system characterized by "one core, two nuclei, and multiple uses," focusing on core chromatography column technology and expanding into various product and service applications [6]. - The company is committed to continuous R&D investment and has established platforms such as provincial engineering research centers to tackle key technologies and enhance industrialization [6]. Domestic Substitution Progress - The domestic substitution of chromatography separation and purification equipment is at a critical stage, with Hanbang Technology leading in small molecule production equipment and accelerating its market share in large molecule equipment [7]. - The company has established three differentiated advantages: competitive product performance, localized service capabilities, and a comprehensive product line offering customized solutions [7]. Strategic Focus for the 14th Five-Year Plan - The "14th Five-Year Plan" emphasizes high-quality development and technological self-reliance, presenting significant opportunities for the biopharmaceutical upstream equipment industry [8]. - Hanbang Technology is focusing on three key areas: large molecule biopharmaceuticals, nucleic acid and peptide drugs, and the domestic substitution of chromatography fillers, aiming to break the monopoly of foreign brands [8].
汉邦科技汤业峰：IPO赋能高质量发展，锚定生物医药赛道国产替代新机遇